Pharmaceuticals News and Research

RSS

OTC asthma inhaler endangers patients by encouraging substandard treatment

An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.

20 Feb 2014

PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new service line designed to provide a focused, market-driven approach to regulatory outsourcing services in the life sciences industry, with a primary emphasis on post-approval regulatory activities.

From Parexel 19 Feb 2014

First Edition: February 19, 2014

Today's headlines include reports about the doubts that now surround Arkansas' Medicaid expansion plan -- a compromise plan that has gained national attention.

19 Feb 2014

Neuropsychological assessment efficiently tracks disease progression in memory clinic patients

Investigators at the University of Amsterdam, The Netherlands, have shown that progression of disease in memory clinic patients can be tracked efficiently with 45 minutes of neuropsychological testing. MRI measures of brain atrophy were shown to be less reliable to pick up changes in the same patients.

19 Feb 2014

Ajoene in garlic prevents bacteria from destroying white blood cells

Aggressive multi-resistant infections constitute an increasing health problem all over the world. Bacteria are developing resistance at an alarming pace, so new pharmaceuticals that can combat this threat are in great demand.

19 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

Validic Labs launched to bridge the gap between healthcare companies and mHealth data producers

Validic, pioneer of the first truly inclusive mobile health marketplace, announced today the latest innovation to its data-leveraging platform. Validic has launched Validic Labs in an effort to further bridge the gap between mHealth data producers and healthcare companies. Validic Labs facilitates a simple connection between the app and device developers and the healthcare system in an effort to foster faster, more productive healthcare innovation on both sides.

18 Feb 2014

First Edition: February 18, 2014

Kaiser Health News staff writer Jay Hancock, working in collaboration with USA Today, reports: "Congratulations. You bought insurance through one of the online Affordable Care Act exchanges, possibly after days or weeks of trying to get the site to work. Don't relax. Joining the plan is only the first challenge. Now you have to understand it. Policies sold through the online portals -- to more than 3 million people so far -- cover essential benefits and put a cap on your out-of-pocket medical costs. But you need to follow the rules" (Hancock, 2/17).

18 Feb 2014

New drug patent may help overcome problems associated with MDR-TB

A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics.

18 Feb 2014

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that the Food and Drug Administration has granted Fast Track designation to the GFT505 development program in NASH, with effect from February 14, 2014.

18 Feb 2014

High levels of stress hormone cortisol may contribute to risk aversion in traders

High levels of the stress hormone cortisol may contribute to the risk aversion and 'irrational pessimism' found among bankers and fund managers during financial crises, according to a new study.

18 Feb 2014

Researchers discover key role of actin in shutting down endocytosis during mitosis

Researchers from Warwick Medical School have discovered the key role of a protein in shutting down endocytosis during mitosis, answering a question that has evaded scientists for half a century.

18 Feb 2014

Experts sound alarm about the dangers of industrial chemicals on children’s health

In a Review published in The Lancet Neurology, two of the world’s leading experts on the link between environment and children’s health are sounding the alarm on the dangers of industrial chemicals. They are calling on countries to transform their chemical risk-assessment procedures in order to protect children from everyday toxins that may be causing a global “silent epidemic” of brain development disorders.

18 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Researchers use new technique that can partially move tumors from inoperable locations in brain

One factor that makes glioblastoma cancers so difficult to treat is that malignant cells from the tumors spread throughout the brain by following nerve fibers and blood vessels to invade new locations.

17 Feb 2014

Johns Hopkins experts identify major sources of high cancer costs

In a review article published Feb. 14 in The Lancet Oncology, Johns Hopkins experts identify three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging and drug pricing.

17 Feb 2014

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Pharmaceuticals News and Research

OTC asthma inhaler endangers patients by encouraging substandard treatment

PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry

First Edition: February 19, 2014

Neuropsychological assessment efficiently tracks disease progression in memory clinic patients

Ajoene in garlic prevents bacteria from destroying white blood cells

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

Validic Labs launched to bridge the gap between healthcare companies and mHealth data producers

First Edition: February 18, 2014

New drug patent may help overcome problems associated with MDR-TB

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

High levels of stress hormone cortisol may contribute to risk aversion in traders

Researchers discover key role of actin in shutting down endocytosis during mitosis

Experts sound alarm about the dangers of industrial chemicals on children’s health

Novartis acquires CoStim Pharmaceuticals

Researchers use new technique that can partially move tumors from inoperable locations in brain

Johns Hopkins experts identify major sources of high cancer costs

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence